ReAlta Life Sciences Announces New Research Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate RLS-0071 as a Medical Countermeasure for Acute Radiation Syndrome
ReAlta Life Announces Dosing of First Patient in Phase 2 Trial of RLS-0071
ReAlta Life Sciences Strengthens Board of Directors with Appointment of Two Accomplished Biotechnology Innovators
ReAlta Life Sciences Strengthens Board of Directors
ReAlta Life Sciences Receives FDA Clearance for Phase 2 Trial of RLS-0071
ReAlta Life Sciences Receives FDA Clearance for Phase 2 Trial of RLS-0071 in Hospitalized Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
ReAlta Life Sciences Announces Poster Presentation at the European Respiratory Society 2023 International Congress
ReAlta Life Sciences Doses First Patient in Phase 2 STAR-Study of RLS-0071 for Hypoxic Ischemic Encephalopathy in Newborns
ReAlta Life Sciences Announces Poster Presentation at the American Thoracic Society 2023 Annual Meeting
NORFOLK, Va.--(BUSINESS WIRE)--ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE). RLS-0071 is the Company’s lead dual action complement inhibitor and innate anti-inflammatory peptide.